This study investigates if certain substances that might cause bone destruction are found in higher levels in the blood or bone marrow of people with myeloma. Myeloma is a type of cancer that affects plasma cells in the bone marrow. The study will compare these levels in patients with newly diagnosed and relapsed myeloma to healthy individuals.
Participants in the study will have their blood and bone marrow tested for specific substances. These include serum FGF23, heparanase, Dkk1, and plasma klotho levels. These tests will help researchers understand the differences between myeloma patients and healthy controls.
- Who can participate: Participants must speak English, have no liver or kidney disorders, and no history of cancer in the past 5 years, except certain skin cancers. They should not be pregnant, allergic to xylocaine, have had a recent acute illness, bleeding disorders, or be prisoners.
- Study details: Participants will undergo blood and bone marrow tests to measure levels of certain substances. These tests are part of the exploratory study to understand differences in myeloma patients.
How understandable was the trial content above?
Hard to understand
Easy to understand
